Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
N Engl J Med
.
2024 Mar 21;390(12):1153-1154.
doi: 10.1056/NEJMc2401126.
Authors
Dion Groothof
1
,
Stephan J L Bakker
1
,
Nicole S Erler
2
Affiliations
1
University Medical Center Groningen, Groningen, the Netherlands d.groothof@umcg.nl.
2
Erasmus University Medical Center, Rotterdam, the Netherlands.
PMID:
38507767
DOI:
10.1056/NEJMc2401126
No abstract available
Publication types
Letter
Comment
MeSH terms
Glomerulosclerosis, Focal Segmental* / drug therapy
Humans
Irbesartan / therapeutic use
Spiro Compounds*
Sulfonamides
Substances
Irbesartan
sparsentan
Spiro Compounds
Sulfonamides